RLM.L Regulatory News (RLM)

10 January 2013

PuriCore plc

("PuriCore" or the "Company")

PuriCore (LSE: PURI), the water-based, clean technology company, today announces Board changes. In line with corporate governance best practice and following his long-standing service as a Non-Executive Director, Mike Sapountzoglou is stepping down with effect from 11 January 2013. The Company also announces that Daniel Hegglin will join PuriCore as a Non-Executive Director.

Mr. Hegglin offers more than 30 years of experience in international finance. He is currently a partner at TT International, a Hong Kong investment management fund, where he is responsible for its hedge fund and Asia businesses. Mr. Hegglin was previously with Morgan Stanley in Europe and Asia for 24 years.

Mr. Hegglin's appointment as a Non-Executive Director will be effective upon admission to listing and trading of the new ordinary shares to be issued by the Company following approval of the resolution at the General Meeting of the Company held earlier today. Admission is expected on 11 January 2013. Mr. Hegglin will, immediately following admission, hold 3,309,091 shares in the Company, being 6.61 per cent. of the enlarged issued share capital.

The Company confirms that there is no additional information about Mr. Hegglin that the Company is required to disclose under paragraph 9.6.13(1) to (6) of the Listing Rules of the UK Listing Authority.

Michael Ashton, Executive Chairman, said:

"Mike's decision to leave comes at a time when the Company is entering an exciting new phase, to which he has been an integral part, and we wish him well for the future. The addition of Danny, whom I've recently come to know and respect, will refresh the Board with additional financial sector experience."

Enquiries:

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary solutions that protect people from the spread of infectious pathogens without causing harm to human health or the environment. The Company's products are used in a broad range of markets that depend upon effective pathogen control including MRSA, e.Coli, and C. difficile. PuriCore is a leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients in UK hospitals. The Company's products are the de facto standard for food safety in leading US supermarket chains. PuriCore also offers a breakthrough wound therapy solution to treat chronic and acute wounds including diabetic ulcers and burns. PuriCore has operations in Malvern, Pennsylvania, US, and in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com, which does not form part of this announcement.